Photo of Harold J. Burstein,  MD, PhD

Harold J. Burstein, MD, PhD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 632-3495
Fax: (617) 632-3479


hburstein@partners.org

Harold J. Burstein, MD, PhD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Associate Professor, Medicine, Harvard Medical School
  • Staff Physician, Medicine, Brigham And Women's Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

Research interests include therapies for early-stage and advanced breast cancer, including neoadjuvant treatments, concurrent radiotherapy/chemotherapy and biological therapies. In addition, I am intrested in use of alternative medicine by women with breast cancer, health care for breast cancer surviors, and quality of life and physhosocial issues among wmoen with histories of breast cancer.

Publications

Powered by Harvard Catalyst
  • Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, Dizon DS, Fine HA, Kalemkerian GP, Moasser M, Neuss MN, O'Day SJ, Odenike O, Ryan CJ, Schilsky RL, Schwartz GK, Venook AP, Wong SL, Patel JD. Clinical cancer advances 2015: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol 2015; 33:786-809. PubMed
  • Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD, , . Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2015; 372:436-46. PubMed
  • Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 2015; 372:134-41. PubMed
  • Shulman LN, Berry DA, Cirrincione CT, Becker HP, Perez EA, O'Regan R, Martino S, Shapiro CL, Schneider CJ, Kimmick G, Burstein HJ, Norton L, Muss H, Hudis CA, Winer EP. Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance). J Clin Oncol 2014; 32:2311-7. PubMed
  • Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, Gonzalez-Angulo AM, Moy B, Rugo HS, Theriault RL, Weeks JC, Winer EP, Lin NU. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol 2014. PubMed
  • Sledge GW, Mamounas EP, Hortobagyi GN, Burstein HJ, Goodwin PJ, Wolff AC. Past, Present, and Future Challenges in Breast Cancer Treatment. J Clin Oncol 2014. PubMed
  • Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA, . Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. N Engl J Med 2014. PubMed
  • Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ, Stearns V, Winer EP, Griggs JJ. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. J Clin Oncol 2014. PubMed
  • Lyman GH, Temin S, Edge SB, Newman LA, Turner RR, Weaver DL, Benson AB, Bosserman LD, Burstein HJ, Cody H, Hayman J, Perkins CL, Podoloff DA, Giuliano AE. Sentinel lymph node biopsy for patients with early-stage breast cancer: american society of clinical oncology clinical practice guideline update. J Clin Oncol 2014; 32:1365-83. PubMed
  • Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Marcom PK, Mayer IA, McCormick B, Miller RS, Pegram M, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R. Breast cancer version 3.2014. J Natl Compr Canc Netw 2014; 12:542-90. PubMed
  • Burstein HJ. Neoadjuvant pertuzumab: the exception that proves the rule? Oncology (Huntingt) 2014; 28:197-9. PubMed
  • Seah DS, Luis IV, Macrae E, Sohl J, Litsas G, Winer EP, Lin NU, Burstein HJ. Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. J Natl Compr Canc Netw 2014; 12:71-80. PubMed
  • Burstein HJ. Fifty years of systemic therapy for breast cancer: from one size fits all to tailored therapy. Am Soc Clin Oncol Educ Book 2014; 34:e1-3. PubMed
  • Krop IE, Burstein HJ. Trastuzumab: qui bono? Journal of the National Cancer Institute 2013; 105:1772-5. PubMed
  • Ruddy KJ, Desantis SD, Gelman RS, Wu AH, Punglia RS, Mayer EL, Tolaney SM, Winer EP, Partridge AH, Burstein HJ. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice. Breast Cancer Res Treat 2013; 141:421-7. PubMed
  • Burstein HJ. Breast cancer treatment in the era of individualized care. Hematol Oncol Clin North Am 2013; 27:xiii-xv. PubMed
  • Vaz-Luis I, Seah D, Olson EM, Wagle N, Metzger-Filho O, Sohl J, Litsas G, Burstein HJ, Krop IE, Winer EP, Lin NU. Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study. Clin Breast Cancer 2013; 13:254-63. PubMed
  • Burstein HJ. Patients with triple negative breast cancer: is there an optimal adjuvant treatment? Breast 2013; 22 Suppl 2:S147-8. PubMed
  • Theriault RL, Carlson RW, Allred C, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R, . Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2013; 11:753-60; quiz 761. PubMed
  • Burstein HJ. Lou Gehrig, Angelina Jolie, and cancer genetics. J Natl Compr Canc Netw 2013; 11:631-2. PubMed
  • Bunnell CA, Gross AH, Weingart SN, Kalfin MJ, Partridge A, Lane S, Burstein HJ, Fine B, Hilton NA, Sullivan C, Hagemeister EE, Kelly AE, Colicchio L, Szabatura AH, Winer EP, Salisbury M, Mann S. High performance teamwork training and systems redesign in outpatient oncology. BMJ Qual Saf 2013; 22:405-13. PubMed
  • Burstein HJ. Off-label use of oncology drugs: too much, too little, or just right? J Natl Compr Canc Netw 2013; 11:505-6. PubMed
  • Olson EM, Najita JS, Sohl J, Arnaout A, Burstein HJ, Winer EP, Lin NU. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast 2013. PubMed
  • Bellon JR, Wong JS, Burstein HJ. Should Response to Preoperative Chemotherapy Affect Radiotherapy Recommendations After Mastectomy for Stage II Breast Cancer? J Clin Oncol 2012; 30:3916-20. PubMed
  • Mayer EL, Isakoff SJ, Klement G, Downing SR, Chen WY, Hannagan K, Gelman R, Winer EP, Burstein HJ. Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics. Breast Cancer Res Treat 2012; 136:169-78. PubMed
  • Burstein HJ. A "shot heard 'round the world" on cancer drug costs? J Natl Compr Canc Netw 2012; 10:1315-6. PubMed
  • Lyman GH, Burstein HJ, Buzdar AU, D'Agostino R, Ellis PA. Making genuine progress against metastatic breast cancer. J Clin Oncol 2012; 30:3448-51. PubMed
  • Burstein HJ. Assuring access to academic cancer centers. J Natl Compr Canc Netw 2012; 10:1177-8. PubMed
  • Burstein HJ. Pathway-based oncology care: time for more transparency. J Natl Compr Canc Netw 2012; 10:1043-4. PubMed
  • Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol 2012; 30:2585-92. PubMed
  • Carlson RW, Allred DC, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Soliman H, Somlo G, Theriault RL, Ward JH, Wolff AC, Zellars R, Kumar R, Shead DA, . Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012; 10:821-9. PubMed
  • Burstein HJ. Simplifying guidelines: we only need one adjuvant chemotherapy regimen for breast cancer. J Natl Compr Canc Netw 2012; 10:797-8. PubMed
  • Burstein HJ, Piccart-Gebhart MJ, Perez EA, Hortobagyi GN, Wolmark N, Albain KS, Norton L, Winer EP, Hudis CA. Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? J Clin Oncol 2012; 30:2179-82. PubMed
  • Burstein HJ. The top five in oncology: where do we go from here? J Natl Compr Canc Netw 2012; 10:681-2. PubMed
  • Burstein HJ. Bevacizumab for Advanced Breast Cancer: All Tied Up With a RIBBON? J Clin Oncol 2011; 29:1232-5. PubMed
  • Burstein HJ. Mind the gap. J Natl Compr Canc Netw 2011; 9:343. PubMed
  • Lin NU, Burstein HJ. EMBRACE, eribulin, and new realities of advanced breast cancer. Lancet 2011; 377:878-80. PubMed
  • Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Sachdev J, Smith ML, Somlo G, Ward JH, Wolff AC, Zellars R. Invasive breast cancer. J Natl Compr Canc Netw 2011; 9:136-222. PubMed
  • Choueiri TK, Mayer EL, Je Y, Rosenberg JE, Nguyen PL, Azzi GR, Bellmunt J, Burstein HJ, Schutz FA. Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab. J Clin Oncol 2011. PubMed
  • Burstein HJ. Beaten at the alamo by the europeans. J Natl Compr Canc Netw 2011; 9:1. PubMed
  • Burstein HJ. Board recertification. J Natl Compr Canc Netw 2010; 8:1111. PubMed
  • Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Somlo G, Topham NS, Ward JH, Winer EP, Wolff AC. Breast cancer: noninvasive and special situations. J Natl Compr Canc Netw 2010; 8:1182-207. PubMed
  • Burstein HJ. Avastin, ODAC, and the FDA: Are We Drafting the Right Players? J Natl Compr Canc Netw 2010; 8:833-4. PubMed
  • Burstein HJ, Griggs JJ, Prestrud AA, Temin S. American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Oncol Pract 2011; 6:243-6. PubMed
  • Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ, . American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010; 28:3784-96. PubMed
  • Burstein HJ, Griggs JJ. Adjuvant hormonal therapy for early-stage breast cancer. Surg Oncol Clin N Am 2010; 19:639-47. PubMed
  • Burstein HJ. Re-engineering the cooperative groups. J Natl Compr Canc Netw 2010; 8:505. PubMed
  • Burstein HJ, Sun Y, Dirix LY, Jiang Z, Paridaens R, Tan AR, Awada A, Ranade A, Jiao S, Schwartz G, Abbas R, Powell C, Turnbull K, Vermette J, Zacharchuk C, Badwe R. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010; 28:1301-7. PubMed
  • Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010; 28:1124-30. PubMed
  • Burstein HJ, Winer EP. Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy. J Clin Oncol 2009; 27:5671-3. PubMed
  • Burstein HJ. Screening contretemps: the real issue in the mammogram guideline debate. J Natl Compr Canc Netw 2009; 7:1039-40. PubMed
  • Burstein HJ. What is a patient navigator, and should we have them in major cancer centers? J Natl Compr Canc Netw 2009; 7:905. PubMed
  • Burstein HJ. Late effects of adjuvant systemic therapies in women diagnosed with breast cancer at a young age. Breast 2009; 18 Suppl 3:S135-6. PubMed
  • Allred DC, Carlson RW, Berry DA, Burstein HJ, Edge SB, Goldstein LJ, Gown A, Hammond ME, Iglehart JD, Moench S, Pierce LJ, Ravdin P, Schnitt SJ, Wolff AC. NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. J Natl Compr Canc Netw 2009; 7 Suppl 6:S1-S21; quiz S22-3. PubMed
  • Stubblefield MD, Burstein HJ, Burton AW, Custodio CM, Deng GE, Ho M, Junck L, Morris GS, Paice JA, Tummala S, Von Roenn JH. NCCN task force report: management of neuropathy in cancer. J Natl Compr Canc Netw 2009; 7 Suppl 5:S1-S26; quiz S27-8. PubMed
  • Burstein HJ. Colon cancer: the new breast cancer. J Natl Compr Canc Netw 2009; 7:773. PubMed
  • Abel GA, Burstein HJ, Hevelone ND, Weeks JC. Cancer-related direct-to-consumer advertising: awareness, perceptions, and reported impact among patients undergoing active cancer treatment. J Clin Oncol 2009; 27:4182-7. PubMed
  • Burstein HJ, Souter I, D'Alessandro HA, Sgroi DC. Case records of the Massachusetts General Hospital. Case 25-2009. A 36-year-old woman with hormone-receptor-positive breast cancer. N Engl J Med 2009; 361:699-707. PubMed
  • Burstein HJ. Quality measures, clinical practice, NCCN, and McAllen, Texas. J Natl Compr Canc Netw 2009; 7:695. PubMed
  • Muss HB,Berry DA,Cirrincione CT,Theodoulou M,Mauer AM,Kornblith AB,Partridge AH,Dressler LG,Cohen HJ,Becker HP,Kartcheske PA,Wheeler JD,Perez EA,Wolff AC,Gralow JR,Burstein HJ,Mahmood AA,Magrinat G,Parker BA,Hart RD,Grenier D,Norton L,Hudis CA,Winer EP. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009; 360:2055-65. PubMed
  • Burstein HJ. By the way, doctor. I've been having PET-CT scans to look for any growth or spread of previously removed tumors. Are they as reliable in detecting breast cancer as a regular mammogram? Harv Health Lett 2009; 34:2. PubMed
  • Burstein HJ Jr. Do clinical trials belong in clinical guidelines? J Natl Compr Canc Netw 2009; 7:489. PubMed
  • Bafford AC,Burstein HJ,Barkley CR,Smith BL,Lipsitz S,Iglehart JD,Winer EP,Golshan M. Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Res Treat 2008; 115:7-12. PubMed
  • Burstein HJ Jr. SPIKES for Difficult Conversations with Cancer Patients. J Natl Compr Canc Netw 2009; 7:341. PubMed
  • Carlson RW,Allred DC,Anderson BO,Burstein HJ,Carter WB,Edge SB,Erban JK,Farrar WB,Goldstein LJ,Gradishar WJ,Hayes DF,Hudis CA,Jahanzeb M,Kiel K,Ljung BM,Marcom PK,Mayer IA,McCormick B,Nabell LM,Pierce LJ,Reed EC,Smith ML,Somlo G,Theriault RL,Topham NS,Ward JH,Winer EP,Wolff AC. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2009; 7:122-92. PubMed
  • Burstein HJ. Personalized medicine and breast cancer care. J Natl Compr Canc Netw 2009; 7:109. PubMed
  • Nunes RA,Li X,Kang SP,Burstein H,Roberts L,Carney W,Blackwell K,Ryan P,Borges V,Iglehart JD,Friedman P,Harris LN. Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy. Int J Biol Markers 2009; 24:1-10. PubMed
  • Burstein HJ,Chen YH,Parker LM,Savoie J,Younger J,Kuter I,Ryan PD,Garber JE,Chen H,Campos SM,Shulman LN,Harris LN,Gelman R,Winer EP. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res 2008; 14:7871-7. PubMed
  • Burstein HJ. Conflict of interest and oncology guidelines. J Natl Compr Canc Netw 2009; 6:955. PubMed
  • Burstein HJ. Oncology teamwork. J Natl Compr Canc Netw 2008; 6:715. PubMed
  • Figlin RA,Brown E,Armstrong AJ,Akerley W,Benson AB 3rd,Burstein HJ,Ettinger DS,Febbo PG,Fury MG,Hudes GR,Kies MS,Kwak EL,Morgan RJ Jr,Mortimer J,Reckamp K,Venook AP,Worden F,Yen Y. NCCN Task Force Report: mTOR inhibition in solid tumors. J Natl Compr Canc Netw 2008; 6 Suppl 5:S1-S20; quiz S21-S22. PubMed
  • Tolaney SM,Najita J,Winer EP,Burstein HJ. Lymphopenia associated with adjuvant anthracycline/ taxane regimens. Clin Breast Cancer 2008; 8:352-6. PubMed
  • Burstein HJ, Storniolo AM, Franco S, Forster J, Stein S, Rubin S, Salazar VM, Blackwell KL. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 2008; 19:1068-74. PubMed
  • Punglia RS, Burstein HJ, Winer EP, Weeks JC. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. Journal of the National Cancer Institute 2008; 100:642-8. PubMed
  • Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, Winer EP. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008; 26:1993-9. PubMed
  • Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008; 26:1810-6. PubMed
  • Burstein HJ. Preoperative therapy as a model for translational research in breast cancer. Cancer Invest 2008; 26:217-21. PubMed
  • Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leu J Clin Oncol 2008; 26:1642-9. PubMed
  • Mayer EL, Burstein HJ. Weighing a dose-dense option for adjuvant chemotherapy and trastuzumab in early-stage breast cancer. J Clin Oncol 2008; 26:1198-200. PubMed
  • Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, Buzdar AU, Smith IE, Symmans WF, Singh B, Winer EP. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 2008; 26:814-9. PubMed
  • Burstein HJ, Schwartz RS. Molecular origins of cancer. N Engl J Med 2008; 358:527. PubMed
  • Burstein HJ. Cognitive side-effects of adjuvant treatments. Breast 2007; 16 Suppl 2:S166-8. PubMed
  • Burstein HJ, Winer EP. Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol 2007; 25:3797-9. PubMed
  • Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert-Falls R, Marcom PK, Gelman R, Winer EP. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 2007; 110:965-72. PubMed
  • Lin NU, Parker LM, Come SE, Burstein HJ, Haldoupis M, Ryabin N, Gelman R, Winer EP, Shulman LN. Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Invest New Drugs 2007; 25:369-75. PubMed
  • Burstein HJ. Aromatase inhibitor-associated arthralgia syndrome. Breast 2007; 16:223-34. PubMed
  • Podoloff DA, Advani RH, Allred C, Benson AB 3rd, Brown E, Burstein HJ, Carlson RW, Coleman RE, Czuczman MS, Delbeke D, Edge SB, Ettinger DS, Grannis FW Jr, Hillner BE, Hoffman JM, Kiel K, Komaki R, Larson SM, Mankoff DA, Rosenzweig KE, Skibber JM, Yahalom J, Yu JM, Zelenetz AD. NCCN Task Force Report: Positron Emission Tomography (PET)/Computed Tomography (CT) Scanning in Cancer. J Natl Compr Canc Netw 2007; 5 Suppl 1:S1-S22. PubMed
  • Mayer EL, Burstein HJ. Chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am 2007; 21:257-72. PubMed
  • Burstein HJ. Anemia in cancer: update on studies of erythropoiesis-stimulating agents. J Support Oncol 2007; 5:5-26. PubMed
  • Burstein HJ, Overmoyer B, Gelman R, Silverman P, Savoie J, Clarke K, Dumadag L, Younger J, Ivy P, Winer EP. Rebeccamycin analog for refractory breast cancer: a randomized phase II trial of dosing schedules. Invest New Drugs 2006; 25:161-4. PubMed
  • Burstein HJ. Biological basis of breast cancer: an introduction. Semin Oncol 2007; 34:S1-3. PubMed
  • Mayer EL, Lin NU, Burstein HJ. Novel approaches to advanced breast cancer: bevacizumab and lapatinib. J Natl Compr Canc Netw 2007; 5:314-23. PubMed
  • Miller KD, Sledge GW, Burstein HJ. Angiogenesis inhibition in the treatment of breast cancer: a review of studies presented at the 2006 san antonio breast cancer symposium. Clin Adv Hematol Oncol 2007; 5:1-12. PubMed
  • Carlson RW, Anderson BO, Burstein HJ, Carter WB, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Ljung BM, Kiel K, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff AC. Invasive breast cancer. J Natl Compr Canc Netw 2007; 5:246-312. PubMed
  • Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, Ryan PD, Come SE, Burstein HJ, Lesnikoski BA, Kamma M, Friedman PN, Gelman R, Iglehart JD, Winer EP. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 2007; 13:1198-207. PubMed
  • Burstein HJ. Myeloid growth factor support for dose-dense adjuvant chemotherapy for breast cancer. Oncology (Huntingt) 2007; 20:13-5. PubMed
  • Tolaney SM, Partridge AH, Sheib RG, Burstein HJ, Winer EP. Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer. J Clin Oncol 2006; 24:5330-1. PubMed
  • Sledge GW, Rugo HS, Burstein HJ. The role of angiogenesis inhibition in the treatment of breast cancer. Clin Adv Hematol Oncol 2006; 4 Suppl 21:1-12. PubMed
  • Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ, Hudis CA, Jahanzeb M, Stark A, Wolff AC, Press MF, Winer EP, Paik S, Ljung BM,. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 2006; 4 Suppl 3:S1-22; quiz S23-4. PubMed
  • Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis. Cancer 2006; 106:2576-82. PubMed
  • Burstein HJ, Mayer E, Patridge AH, O'Kane H, Litsas G, Come SE, Hudis CA, Goldstein DF, Muss HB, Winter EP, Garber JE. Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons. Clin Breast Cancer 2006; 7:158-61. PubMed
  • Carlson RW, Brown E, Burstein HJ, Gradishar WJ, Hudis CA, Loprinzi C, Mamounas EP, Perez EA, Pritchard K, Ravdin P, Recht A, Somlo G, Theriault RL, Winer EP, Wolff AC,. NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw 2006; 4 Suppl 1:S1-26. PubMed
  • Burstein HJ, Bellon JR, Galper S, Lu HM, Kuter I, Taghian AG, Wong J, Gelman R, Bunnell CA, Parker LM, Garber JE, Winer EP, Harris JR, Powell SN. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. Int J Radiat Oncol Biol Phys 2006; 64:496-504. PubMed
  • Peppercorn J, Partridge A, Burstein HJ, Winer EP. Standards for follow-up care of patents with breast cancer. Breast 2005; 14:500-8. PubMed
  • Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH, Schapira L, Ryan PD, Younger J, Harris LN, Moy B, Come SE, Schumer ST, Bunnell CA, Haldoupis M, Gelman R, Winer EP. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol 2005; 23:8340-7. PubMed
  • Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol 2005; 23:5178-87. PubMed
  • Burstein HJ, Winer EP. HER2 or Not HER2: That Is the Question. J Clin Oncol 2005; 23:3656-9. PubMed
  • Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2004; 23:619-29. PubMed
  • Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med 2004; 350:1430-41. PubMed
  • Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003; 21:2889-95. PubMed
  • Winer EP, Hudis C, Burstein HJ, Bryant J, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gelber R, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol 2003; 21:2597-9. PubMed
  • Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003; 97:2972-7. PubMed
  • Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP. Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat 2003; 79:391-7. PubMed
  • Earle CC, Burstein HJ, Winer EP, Weeks JC. Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol 2003; 21:1447-51. PubMed
  • Partridge AH, Burstein HJ, Gelman RS, Marcom PK, Winer EP. Do patients participating in clinical trials want to know study results? J Natl Cancer Inst 2003; 95:491-2. PubMed
  • Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL, Winer EP. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2002; 21:46-53. PubMed
  • Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol 2002; 20:3317-27. PubMed
  • Jeter MD, J. Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys 2002; 53:394-400. PubMed
  • Burstein HJ, Bunnell CA, Winer EP. New cytotoxic agents and schedules for advanced breast cancer. Semin Oncol 2001; 28:344-58. PubMed
  • Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19:2722-30. PubMed
  • Burstein HJ, Swanson SJ, Christian RL, McMenamin ME. Unusual aspects of breast cancer: case 2. Synchronous bilateral lung and breast cancers. J Clin Oncol 2001; 19:2571-3. PubMed
  • Partridge AH, Burstein HJ, Winer EP. Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr 2002. PubMed
  • Winer EP, Burstein HJ. New combinations with Herceptin in metastatic breast cancer. Oncology 2001; 61 Suppl 2:50-7. PubMed
  • Burstein HJ, Winer EP. Primary care for survivors of breast cancer. N Engl J Med 2000; 343:1086-94. PubMed
  • Burstein HJ. Discussing complementary therapies with cancer patients: what should we be talking about? J Clin Oncol 2000; 18:2501-4. PubMed
  • Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000; 18:1212-9. PubMed
  • Curigliano G, Mayer EL, Burstein HJ, Winer EP, Goldhirsch A. Cardiac toxicity from systemic cancer therapy: a comprehensive review. Prog Cardiovasc Dis 2010; 53:94-104. PubMed
  • Schwartz GF, Bartelink H, Burstein HJ, Cady B, Cataliotti L, Fentiman IS, Holland R, Hughes KS, Masood S, McCormick B, Palazzo JA, Pressman PI, Reis-Filho J, Pusztai L, Rutgers EJ, Seidman AD, Solin LJ, Sparano JA. Adjuvant therapy in stage I carcinoma of the breast: the influence of multigene analyses and molecular phenotyping. Breast J 2012; 18:303-11. PubMed
  • Burstein HJ, Ramirez MJ, Petros WP, Clarke KD, Warmuth MA, Marcom PK, Matulonis UA, Parker LM, Harris LN, Winer EP. Phase I study of Doxil and vinorelbine in metastatic breast cancer. Ann Oncol 1999; 10:1113-6. PubMed
  • Burstein HJ, Gelber S, Guadagnoli E, Weeks JC. Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 1999; 340:1733-9. PubMed
  • Abbas AK, Burstein HJ, Bogen SA. Determinants of helper T cell-dependent antibody production. Semin Immunol 1993; 5:441-7. PubMed
  • Burstein HJ, Shea CM, Abbas AK. Aqueous antigens induce in vivo tolerance selectively in IL-2- and IFN-gamma-producing (Th1) cells. J Immunol 1992; 148:3687-91. PubMed
  • Burstein HJ, Tepper RI, Leder P, Abbas AK. Humoral immune functions in IL-4 transgenic mice. J Immunol 1991; 147:2950-6. PubMed
  • Abbas AK, Williams ME, Burstein HJ, Chang TL, Bossu P, Lichtman AH. Activation and functions of CD4+ T-cell subsets. Immunol Rev 1991; 123:5-22. PubMed
Hide